KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Acadia Pharmaceuticals (ACAD) EBIAT (2016 - 2025)

Acadia Pharmaceuticals has reported EBIAT over the past 16 years, most recently at $273.6 million for Q4 2025.

  • Quarterly results put EBIAT at $273.6 million for Q4 2025, up 90.32% from a year ago — trailing twelve months through Dec 2025 was $391.0 million (up 72.66% YoY), and the annual figure for FY2025 was $391.0 million, up 72.66%.
  • EBIAT for Q4 2025 was $273.6 million at Acadia Pharmaceuticals, up from $71.8 million in the prior quarter.
  • Over the last five years, EBIAT for ACAD hit a ceiling of $273.6 million in Q4 2025 and a floor of -$113.1 million in Q1 2022.
  • Median EBIAT over the past 5 years was -$6.7 million (2021), compared with a mean of $8.6 million.
  • Biggest five-year swings in EBIAT: crashed 139.77% in 2023 and later soared 2897.22% in 2024.
  • Acadia Pharmaceuticals' EBIAT stood at -$43.1 million in 2021, then rose by 3.18% to -$41.7 million in 2022, then soared by 209.76% to $45.8 million in 2023, then surged by 213.87% to $143.7 million in 2024, then soared by 90.32% to $273.6 million in 2025.
  • The last three reported values for EBIAT were $273.6 million (Q4 2025), $71.8 million (Q3 2025), and $26.7 million (Q2 2025) per Business Quant data.